Explore
Validate
Learn21339-1-AP
antibody from Proteintech Group
Targeting: RBM39
CAPER, CAPERalpha, CC1.3, fSAP59, HCC1, RNPC2
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [19]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 21339-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#21339-1-AP, RRID:AB_10733352
- Product name
- RBM39 antibody
- Antibody type
- Polyclonal
- Description
- RBM39 antibody (Cat. #21339-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references The sulfonamide anticancer agent indisulam enhances the chemosensitivity of gastric cancer cells by targeting FKBP8.
Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer.
RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B/β-catenin Pathway.
RBM39 Functions as a Potential Oncogene Through the NF-κB Signaling Pathway in Colorectal Cancer Cells.
Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer.
RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA.
The RNA-binding protein RBM39 scaffolds an m⁶A-dependent RNA decay complex that destabilizes Tat transcripts and restricts HIV-1 reactivation.
Xist Repeat A coordinates an assembly of SR proteins to recruit SPEN and induce gene silencing.
Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes.
Rbm39 ameliorates metabolic dysfunction-associated steatotic liver disease by regulating Apob and Fabp4.
LncRNA MCM3AP-AS1 promotes chemoresistance in triple-negative breast cancer through the miR-524-5p/RBM39 axis.
RNA-binding motif protein RBM39 enhances the proliferation of gastric cancer cells by facilitating an oncogenic splicing switch in MRPL33.
RBM39 is a potential prognostic biomarker with functional significance in hepatocellular carcinoma.
Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders.
The cancer-testis lncRNA LINC01977 promotes HCC progression by interacting with RBM39 to prevent Notch2 ubiquitination.
Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells.
Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy.
Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.
Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Li Y, Lu C, Lu J, Jiang H, Li D, Wang Y, Xu G, Wang X, Ma J
The FEBS journal 2026 Mar 20;
The FEBS journal 2026 Mar 20;
Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer.
Yang C, Zheng X, Sun H, Du J, Luo Y, Wang C, Wu Y, Qu L, Yuan F, Yang Z
The Journal of biological chemistry 2026 Apr 15;302(6):111447
The Journal of biological chemistry 2026 Apr 15;302(6):111447
RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B/β-catenin Pathway.
Liu N, Zhang J, Chen W, Ma W, Wu T
Cellular and molecular gastroenterology and hepatology 2025;19(1):101404
Cellular and molecular gastroenterology and hepatology 2025;19(1):101404
RBM39 Functions as a Potential Oncogene Through the NF-κB Signaling Pathway in Colorectal Cancer Cells.
Wang Y, Yang X, Yang Z, Chen Z, Jiang H, Wang Y, Shen D, Su G
Journal of Cancer 2025;16(7):2233-2249
Journal of Cancer 2025;16(7):2233-2249
Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer.
Yan Y, Wang N, Xing B, Yang M, Shang J, Bao Y, Xiao L, Zhang N, Ren Y, Liu C, Chen Y, Han H, Pan Y, Lv L, Zong WX, Ji H, Zhan C, Wang Z, Chen H, Wang Y
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Sep;12(33):e03322
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Sep;12(33):e03322
RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA.
An H, Xia A, Liu S, Luo D, Geng L, Li B, Sun B, Xu Z
Cell proliferation 2025 Oct;58(10):e70059
Cell proliferation 2025 Oct;58(10):e70059
The RNA-binding protein RBM39 scaffolds an m⁶A-dependent RNA decay complex that destabilizes Tat transcripts and restricts HIV-1 reactivation.
Deng X, Xie S, Zhou M, Yuan Q, Wu S, Huang P, Chen M, Zeng J, Guo P, Qin J, Chen C, Liu J, Liu B, He X, Sun L, Zhang H, Li L, Pan T
PLoS biology 2025 Nov;23(11):e3003486
PLoS biology 2025 Nov;23(11):e3003486
Xist Repeat A coordinates an assembly of SR proteins to recruit SPEN and induce gene silencing.
Trotman JB, Porrello A, Schactler SA, DeLeon LE, Eberhard QE, Boyson SP, Zhang Z, Lee DM, Kirik SE, Sultana N, Nguyen SN, Beltejar MG, Shinn MK, Ong SE, Gonzalez-Perez MP, Shaffer SA, Dominguez D, Shechner DM, Calabrese JM
bioRxiv : the preprint server for biology 2025 May 26;
bioRxiv : the preprint server for biology 2025 May 26;
Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes.
Zhang T, Wang S, Zhou Y, Jiao Z, Lu K, Liu X, Li H, Jiang W, Zhang X
PLoS biology 2025 Jun;23(6):e3002846
PLoS biology 2025 Jun;23(6):e3002846
Rbm39 ameliorates metabolic dysfunction-associated steatotic liver disease by regulating Apob and Fabp4.
Zhuang C, Cui F, Chen J, He D, Sun T, Wang P
Biochimica et biophysica acta. Molecular basis of disease 2025 Jun;1871(5):167815
Biochimica et biophysica acta. Molecular basis of disease 2025 Jun;1871(5):167815
LncRNA MCM3AP-AS1 promotes chemoresistance in triple-negative breast cancer through the miR-524-5p/RBM39 axis.
Wang Y, Wang X, Sun H, Zhang Z, Gu J
Molecular and cellular biochemistry 2025 Jan;480(1):371-384
Molecular and cellular biochemistry 2025 Jan;480(1):371-384
RNA-binding motif protein RBM39 enhances the proliferation of gastric cancer cells by facilitating an oncogenic splicing switch in MRPL33.
Lu CP, Li JB, Li DB, Wang YH, Jiang XG, Ma JJ, Xu G
Acta pharmacologica Sinica 2025 Apr;46(4):1068-1081
Acta pharmacologica Sinica 2025 Apr;46(4):1068-1081
RBM39 is a potential prognostic biomarker with functional significance in hepatocellular carcinoma.
Cui F, Wang W, Zhuang C, He D, Wang P
Translational cancer research 2024 Apr 30;13(4):1606-1622
Translational cancer research 2024 Apr 30;13(4):1606-1622
Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders.
Lucas SCC, Ahmed A, Ashraf SN, Argyrou A, Bauer MR, De Donatis GM, Demanze S, Eisele F, Fusani L, Hock A, Kadamur G, Li S, Macmillan-Jones A, Michaelides IN, Phillips C, Rehnström M, Richter M, Rodrigo-Brenni MC, Shilliday F, Wang P, Storer RI
Journal of medicinal chemistry 2024 Apr 11;67(7):5538-5566
Journal of medicinal chemistry 2024 Apr 11;67(7):5538-5566
The cancer-testis lncRNA LINC01977 promotes HCC progression by interacting with RBM39 to prevent Notch2 ubiquitination.
Xia A, Yue Q, Zhu M, Xu J, Liu S, Wu Y, Wang Z, Xu Z, An H, Wang Q, Wang S, Sun B
Cell death discovery 2023 May 18;9(1):169
Cell death discovery 2023 May 18;9(1):169
Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells.
Lu J, Jiang H, Li D, Chen T, Wang Y, Pu Z, Xu G
Journal of proteome research 2021 Sep 3;20(9):4462-4474
Journal of proteome research 2021 Sep 3;20(9):4462-4474
Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy.
Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, Xu W, Wu C, Li J, Zhan F, Wu Y, Yan H
Haematologica 2020 Jun;105(6):1630-1640
Haematologica 2020 Jun;105(6):1630-1640
Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.
Ting TC, Goralski M, Klein K, Wang B, Kim J, Xie Y, Nijhawan D
Cell reports 2019 Nov 5;29(6):1499-1510.e6
Cell reports 2019 Nov 5;29(6):1499-1510.e6
Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bilbao JM, Mackenzie IR
Acta neuropathologica 2012 Nov;124(5):705-16
Acta neuropathologica 2012 Nov;124(5):705-16
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse kidney tissue were subjected to SDS PAGE followed by western blot with 21339-1-AP(RBM39 antibody) at dilution of 1:300
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human pancreas using 21339-1-AP(RBM39 antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The RBM39 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human RBM39. This antibody recognizes human,mouse,rat antigen. The RBM39 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
